Continuous losses, when will REMEGEN emerge from the low point?

① Although it has not yet gotten rid of the dilemma of "increasing revenue without increasing profits," the latest Earnings Reports show that REMEGEN's losses are continuing to narrow; ② In 2024, the company significantly streamlined its R&D pipeline. The company stated that it will continue to dynamically assess the potential of ongoing projects to ensure efficient resource allocation.

cls.cn19:03

[Brokerage Focus] Zhongtai International indicated that REMEGEN (09995) has new indications for its main products and adjusted the rating to "Shareholding."

Gold Wealth News | According to the Research Reports from Zhongtai International, REMEGEN (09995) announced that the injectable Vadisitamab has been approved in China for the treatment of HER2 positive advanced breast cancer with liver metastasis. Clinical studies indicate that the Vadisitamab group significantly extended progression-free survival compared to the commonly used lapatinib combined with capecitabine treatment regimen. Breast cancer is one of the most common gynecological cancers; according to data from the American Cancer Society, the proportion of HER2 positive patients among breast cancer patients is approximately 15%-20%. Domestic studies show that the incidence of liver metastasis in HER2 positive breast cancer patients reaches about 40%-50%, and

Jinwu Financial News09:31 · Ratings

Hong Kong stock mid-term review | The three major indices all rose, with the Hang Seng Index up 1.43%; internet technology and shipping stocks performed well, with Tencent Music and COSCO SHIPPING Development both rising over 12%.

Network Technology stocks are rising, Baidu is up 2.81%, and JD-SW is up 2.70%; Shipping and Ports stocks are also up, COSCO SHIPPING Development is up 12.37%, and PACIFIC BASIN is up 6.67%; Insurance stocks are performing well, CHINA TAIPING is up 6.19%, and China Pacific Insurance is up 4.15%.

Futu NewsMay 14 12:13

Hong Kong stocks movement | REMEGEN (09995) rose over 5% again as the phase III clinical trial of Vedisizumab reached the primary endpoint. The company will choose an appropriate time to submit the new drug marketing application.

REMEGEN (09995) has risen over 5% again, as of the time of writing, it is up 3.7%, at HKD 40.65, with a trading volume of HKD 0.11 billion.

Zhitong FinanceMay 14 10:13

Chinese Stocks Close Mixed on Uncertainty Following Tariff Pause

MT NewswiresMay 13 16:00

RemeGen's Urothelial Carcinoma Drug Shows Positive Results in Clinical Trial; Shares Soar 8%

MT NewswiresMay 13 11:40